TxGuard Small Diameter Vascular Graft

About Annoviant

Annoviant is a private, pre-revenue medical device company developing the TxGuard™ regenerative tissue platform. The technology focuses on overcoming critical failures of existing biological implants—such as calcification, thrombosis, and degeneration—by creating decellularized, stabilized tissues that can be repopulated by the patient's own cells. Its initial pipeline targets pediatric and adult cardiovascular surgeries, with a pulmonary valved conduit for congenital heart disease as the lead program, supported by a $2.99M NIH grant. The company aims to reduce the need for repeat surgeries and improve long-term patient outcomes.

Therapeutic Areas

Other Coronary Artery Bypass Graft (CABG) Surgery Drugs